Comparative Effectiveness and Safety of Rituximab Versus Ocrelizumab in Relapsing-Remitting Multiple Sclerosis: A Finnish Population-Based Matched Cohort Study.

Savolainen M, Soilu-Hänninen M, Nurmi H, Viitala M, Tienari P, Atula S, Laakso SM

Eur J Neurol. 2026 May; 33(5):e70625. PMID: 42141836. Abstract